Photoactivatable ion channel modulator
US-2024409594-A1 · Dec 12, 2024 · US
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling
US9555107B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9555107-B2 |
| Application number | US-201213404241-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 24, 2012 |
| Priority date | Dec 2, 2005 |
| Publication date | Jan 31, 2017 |
| Grant date | Jan 31, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating psoriasis and/or disorders characterized by psoriatic symptoms mediated by IL-22 signaling activity, the method comprising administering to a mammal an effective amount of an anti-IL-22 antibody in a pharmaceutical formulation, wherein the IL-22 antibody is (a) an antibody produced by a hybridoma selected from the group consisting of 3F11.3 (ATCC Accession No. PTA-7312), hybridoma 11H4.4 (ATCC Accession No. PTA-7315), and hybridoma 8E11.9 (ATCC Accession No. PTA-7319); (b) an affinity matured form of the antibody of (a); (c) an antigen-binding fragment of the antibody of (a) or (b); or (d) a humanized form of the antibody of (a), (b), or (c); and wherein psoriatic symptoms mediated by IL-22 signaling activity are alleviated in the mammal. 2. The method of claim 1 further comprising administering at least one antibody selected from the group consisting of an antibody that specifically binds IL20Ra, an antibody that specifically binds IL20Rb, and an antibody that specifically binds IL-22R.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunomodulators · CPC title
Drugs for immunological or allergic disorders · CPC title
of the parathyroid hormones · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9555107B2 cover?
- Compositions and methods are provided for the diagnosis and treatment of inflammation and autoimmune disorders, such as psoriasis. Compositions and methods for modulating IL-23 or IL-22 signaling are provided.
- Who is the assignee on this patent?
- Chen Yvonne M, Chuntharapai Anan, Danilenko Dimitry, and 7 more
- What technology area does this patent fall under?
- Primary CPC classification A61K38/17. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).